Merz drops Obagi bet after Valeant raises bid
This article was originally published in Scrip
Valeant Pharmaceuticals' revised bid to buy dermatology specialist Obagi Medical Products was too rich for Merz Pharma Group's blood, so the German company dropped its public offer to buy Obagi after Valeant raised its acquisition price to $24 per share.
You may also be interested in...
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.